Key result
Extensive endocardial catheter ablation resulted in 89% of patients with ARVC/D remaining free from any ventricular tachycardia recurrence without antiarrhythmic drugs over a mean follow-up of 52 months.
Why the study?
Does extensive endocardial catheter ablation prevent ventricular tachycardia recurrence in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia?
Observational (n=9)
No
Does extensive endocardial catheter ablation prevent ventricular tachycardia recurrence in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia?
Extensive endocardial catheter ablation provides favorable long-term freedom from ventricular tachycardia recurrence in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.
May support extensive endocardial ablation for VT freedom in ARVC/D; leaves open randomized confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hrošová et al. (2012) conducted an observational in Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) with sustained monomorphic ventricular tachycardia (n=9). Endocardial catheter ablation was evaluated on Freedom from any VT recurrence without antiarrhythmic drug. Extensive endocardial catheter ablation resulted in 89% of patients with ARVC/D remaining free from any ventricular tachycardia recurrence without antiarrhythmic drugs over a mean follow-up of 52 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: